Companies › ArriVent BioPharma
3 active drug programs in 5 registered trials: 3 Phase 1, 2 Phase 3; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Firmonertinib Epidermal growth factor receptor erbB1 inhibitor | EGFR | Phase 3 | Metastatic Non-Small Cell Lung Cancer; Non-Small-Cell Lung Cancer; Non-Small Cell Lung Cancer (NSCLC) | Dec 2026 |
| ARR-002 | – | Phase 1 | Ovarian Cancer | Aug 2027 |
| MRG007 (ARR-217) | – | Phase 1 | Locally Advanced or Metastatic Solid Tumors | Mar 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05364073 | Firmonertinib | Phase 1 | Non-Small Cell Lung Cancer (NSCLC) | Oncology | Dec 2026 |
| NCT07755436 | ARR-002 | Phase 1 | Ovarian Cancer | Oncology | Aug 2027 |
| NCT05607550 | Firmonertinib | Phase 3 | Metastatic Non-Small Cell Lung Cancer | Oncology | Feb 2028 |
| NCT07066657 | MRG007 (ARR-217) | Phase 1 | Locally Advanced or Metastatic Solid Tumors | Oncology | Mar 2028 |
| NCT07185997 | Firmonertinib | Phase 3 | Non-Small-Cell Lung Cancer | Oncology | Feb 2029 |
Cash and short-term investments of $393m on 2026-09-30; operating cash outflow about $164m a year; runway about 29 months at that burn, to Feb 2029; 2 of 2 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 12 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
AstraZeneca Shanghai Henlius Biotech Allist Pharmaceuticals Dizal Pharmaceuticals Betta Pharmaceuticals Jiangsu Hansoh Pharmaceutical Johnson & Johnson (Janssen) Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Shanghai JMT-Bio Chia Tai Tianqing Pharmaceutical Group
Jiangsu Alphamab Biopharmaceuticals Nanjing Sanhome Pharmaceutical Black Diamond Therapeutics Jiangsu Aosaikang Pharmaceutical HC Biopharma
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.